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Optimization of a spectrofluorimetric method based on a central 
composite design for the determination of potassium losartan in 
pharmaceutical products
Fatma Demirkaya-Miloglu1,*, Mehmet Emrah Yaman1, Yucel Kadioglu1
1Analytical Chemistry Department, Faculty of Pharmacy, Ataturk University
Here, a spectrofluorimetric method for the determination of potassium losartan (PL) in pharmaceutical 
products is described. The effects of critical parameters, pH, acid molarity, and temperature, on the 
fluorescence intensity of PL were analyzed, and these parameters were optimized using a central composite 
design (CCD). The highest fluorescent intensity at excitation (λex) and emission (λem) wavelengths of 
248 nm and 410 nm, respectively, was achieved using 0.01 M sulfurous acid (pH 2) at 21.6 °C. Under 
optimum conditions, the method was linear from 0.025–0.5 µg/mL, with a reasonably high correlation 
coefficient (0.9993). Furthermore, the method was very sensitive (LOQ, 0.006), accurate (RE, ≤7.06), 
and precise (%RSD, ≤6.51). After development and validation of the method, samples containing PL 
were analyzed with this method, and the obtained data were statistically compared with those obtained 
with a previously published reference method using a two one-sided equivalence test (TOST). According 
to the data, the results from the proposed and reference assays were equivalent.
Uniterms: Potassium losartan/central composite design. Spectrofluorimetry/quantitative analysis. 
Pharmaceutical formulations/quantitative analyis.
Descreve-se método espectrofluorométrico para a determinação de losartana potássica (PL) em produtos 
farmacêuticos. Os efeitos de parâmetros críticos (pH, molaridade ácida e temperatura) na intensidade da 
fluorecência foram otimizados usando o planejamento de componente central (DCC). A mais alta intensidade 
fluorescente com λex=248 nm e λem= 410 nm foi obtida usando ácido sulfúrico 0.01 M (pH 2) e 21.6 ºC. 
Nas condições ideais, a linearidade do método foi estabelecida na faixa de concentração de 0.025-0.5 µg/mL  
com coeficiente de correlação bastante elevado (0.9993). Além disso, o método foi muito sensível com 
valor de LOQ 0.006, exato (RE≤7.06) e preciso (RSD%≤6.51). Depois do desenvolvimento e validação 
do método, amostras de medicamentos contendo PL foram analisadas com este método e os resultados 
obtidos foram comparados estatisticamente com método de referência, publicado anteriormente, usando 
o Teste de equivalência TOST (Teste de Equivalência Unilateral). De acordo com os dados estatísticos, 
os resultados do ensaio de referência e do método proposto foram equivalentes.
Uniterms: Losartana potássica/planejamento de componente central. Espectrofluorimetria/análise 
quantitativa. Formulações farmacêuticas/análise quantitativa.
INTRODUCTION
Several antagonists of angiotensin II receptors, 
which block these receptors, are used to control blood 
pressure (Burnier, Brunner, 1998). Angiotensin II receptor 
antagonists are antihypertensive drugs that block the action 
of angiotensin II by preventing it from binding to receptors 
on blood vessels, and these drugs have no significant side 
effects (Weber, 1997). Intake of these drugs, together with 
lifestyle and dietary changes, by hypertensive patients 
can reduce cardiovascular mortality. Losartan potassium 
(2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-yl phenyl)benzyl 
imidazole-5-methanol mono potassium salt, PL) is an orally 
active, non-peptide antihypertensive agent that specifically 
blocks the angiotensin II type 1 receptor (Burnier, 2001). To 
clarify the functions of PL in the treatment of hypertension, 
simple and rapid analytical methods are needed for the 
routine measurement of this substance.
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A l i t e r a tu re  r ev i ew  showed  tha t  s eve ra l 
analytical methods, including high-performance liquid 
chromatography (HPLC) coupled with UV (Carlucci 
et al., 2000; Erk, 2001; Ozkan, 2001; Hertzog et al., 
2002; Ansari et al., 2004; Bonfilio et al., 2009) or 
fluorescence (Ritter, Furtek, Lo, 1997) detection, UV 
and derivative spectrophotometry methods (Prabhakar, 
Giridhar, 2002; Lastra et al., 2003; Sankar et al., 2003; 
Rahman, Siddiqui, Azmi, 2006; Latheeshjlal et al., 2010; 
El-Shiekh et al., 2011; Rao et al., 2011; Subbarao et al., 
2012), and reversed-phase high-performance thin-layer 
chromatography (HPTLC) (McCarthy et al., 1998), have 
been published for the analysis of PL in pharmaceuticals.
Only two spectrofluorimetric methods have been 
reported for analyzing PL by its native fluorescence in 
an acidic medium (Cagigal et al., 2001; El-Shaboury et 
al., 2012). In one method, reported by El-Shaboury et al. 
(2012), the levels of PL and other sartans were analyzed in 
pharmaceuticals using Teorell and Stenhagen buffer at pH 
2.3. In the other method, which was reported by Cagigal et 
al. (2001), PL and valsartan in human urine were analyzed 
using phosphate buffer at pH 2.
In these studies, it was reported that some external 
parameters, such as the solvent, solvent ratio, acid 
molarity, pH, and temperature, have a strong effect on the 
fluorescence intensity of PL. In the only study of PL in 
pharmaceuticals (El-Shaboury et al., 2012), single factor 
optimization, which does not allow interactions between 
factors, was utilized. This method is not practical because it 
requires numerous experiments to determine the optimum 
of each factor. The central composite design (CCD) was 
used in the proposed study allowed for determination of 
the optimum levels of various factors on the fluorescence 
intensity of PL and the observed interactions between the 
factors.
The aim of this study was to develop, optimize, 
and validate a specific, sensitive, accurate, precise, 
and reproducible quantitative method to determine PL 
in pharmaceutical formulations. A CCD was used to 
examine the effect of acid molarity, pH, and temperature 
on the fluorescence intensity of PL, and to optimize these 
parameters.
EXPERIMENTAL
Reagents and material
PL and sulfurous acid were purchased from Sigma-
Aldrich (Germany). Methanol was purchased from 
Merck (Germany). Ultrapure water was obtained from 
a Milli-Q water purification system (EASYpure RF, 
Barnstead, USA). All other chemicals and solvents were 
of analytical grade and were from commercial sources. 
PL tablets (Cozaar, Eklips, Loxibin, Sarilen, and Sarvas) 
were purchased from the Turkish drug market. Each tablet 
contained 50 mg of PL as the active ingredient.
Stock solutions of 2 mg/mL PL were prepared in 
methanol and were stored at 4 °C. Several sulfurous 
acid solutions were prepared in deionized water at the 
desired concentrations and pH values established by 
the experimental design. Calibration working solutions 
(0.025, 0.05, 0.1, 0.2, 0.3, 0.4, and 0.5 µg/mL) and 
quality control (QC) samples (0.05, 0.2, and 0.4 µg/mL) 
were prepared daily by diluting the stock solution with a 
sulfurous acid solution (0.01 M, pH 2).
Instrumentation
All fluorescence measurements were made with 
an LS 45 spectrofluorophotometer (Perkin Elmer, USA) 
equipped with a xenon lamp and a Monk-Gillieson 
type monochromator (wavelength range, 200-800 nm) 
controlled by a Vestel computer system (TURKEY). The 
instrument excitation and emission slits were adjusted to 
10 nm. The fluorescence of PL was measured at 410 nm, 
with the excitation wavelength set at 248 nm.
Preparation of sample solutions
The sample set  consisted of f ive different 
pharmaceutical preparations that contained 50 mg of PL. 
Ten tablets of each formulation were weighed and finely 
powdered. One tablet, which contained approximately 
50 mg of PL, was placed into a flask with 40 mL of 
methanol. It was sonicated for 15 minutes, cooled to room 
temperature, and the volume was adjusted to 50 mL. The 
concentrations desired for measurements were obtained 
by diluting this stock solution with 0.01 M sulfurous acid 
solution (pH 2).
Experimental design
A CCD was used to optimize the operating parameters 
for determining PL levels in pharmaceuticals. The effect 
of three parameters, requiring n=20 experiments, was 
investigated. The low and high values of the variables 
were chosen based on initial experiments and a review 
of the literature; the pH (A) ranged from 1.5 to 3.0, the 
sulfurous acid concentration (B) ranged from 0.006 M 
to 0.02 M, and the temperature (C) ranged from 20 °C to 
30 °C. All experiments were performed in a randomized 
order to minimize the effects of uncontrolled variables that 
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may introduce bias into the measurements. Six replicates 
of the intermediate values were performed to estimate the 
experimental error.
Software
The experimental design was determined and 
statistical analyses were performed using Excel 2010 
(Microsoft, Redmond, WA, USA), SPSS 11.5 (SPSS, 
Chicago, USA), and Design-Expert 8.0 (Stat-Ease Inc., 
Minneapolis, MN, USA).
RESULTS AND DISCUSSION
Optimization of spectrofluorimetric conditions
Initial experiments on fluorescent intensity
To determine the highest fluorescence intensity 
of PL in its various ionization states, several solvents, 
water, methanol, ethanol, chloroform, ether, acetone, 
acetonitrile, and hexane, were tested with different acid 
solutions under controlled pH values between pH 1.5 and 
3.0 (HNO3, H2SO4, HCl, and H2SO3). PL is very soluble 
TABLE I - Solvent effects on the fluorescence intensity of losartan potassium (PL)
Solvent Acid or buffer λex λem
Fluorescence intensity (IF)
Blank solvent solution PL (0.5 µg/mL)
Water 0.01 M HCl 247.81 387.56 35 428
Methanol 0.01 M HCl 251.08 374.82 43 448
Ethanol 0.01 M HCl 247.75 377.65 65 385
Acetonitrile 0.01 M HCl 279.15 369.12 44 381
Methanol 0.01 M HNO3 252.35 381.70 42 400
0.01 M H2SO4 249.53 383.45 47 372
0.01 M H2SO3 284.12 410.09 16 484
FIGURE 1- Fluorescence spectra (A) of standard PL solutions (0.025–0.5 µg/mL) and (B) a reagent blank (methanol-sulfurous 
acid solution at pH 2.0).
in water, methanol, and ethanol, and it is partially soluble 
in organic solvents such as acetonitrile, chloroform, ether, 
hexane, and acetone. As shown in Table I, the highest PL 
fluorescence intensity was observed in methanol that was 
diluted with a sulfurous acid solution.
These spectra were obtained by measuring the 
fluorescence at excitation and emission wavelengths 
ranging from 210 to 310 nm and from 300 to 500 nm, 
respectively. PL showed a maximum peak at 410 nm 
following excitation at 248 nm (Figure 1A). The sulfurous 
acid solution had no emission peak that interfered with 
that of PL at the studied wavelengths (Figure 1B). This 
absence of interference from the solvent mixture is one 
of the advantages of this method.
Central composite design (CCD)
It is well known that the relative fluorescence 
intensity of a chemical compound is greatly affected 
by chemical variables (solvents, acids, bases, pH, and 
temperature).It was previously reported that PL shows 
native fluorescence only in acidic medium (El-Shaboury 
et al., 2012), because the pKa of PL at 3.15 is acidic. PL 
shows maximum fluorescence at approximately pH 2, 
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and if the medium becomes alkaline, its fluorescence 
intensity decreases. Three studies of the pH optima 
of PL fluorescence found that optimum fluorescence 
was obtained at pH 2–2.5 (El-Shaboury et al., 2012), 
pH 2 (Cagigal et al., 2001), and pH 2.5 (Ritter, Furtek, 
Lo, 1997). We based our experimental design on this 
information, and determined the optimum pH under our 
conditions by varying the pH (A) from 1.5 to 3.
The intensity of fluorescence may also be affected 
by acid concentration. Cagigal et al. (2001) (phosphate 
buffer concentration: 0.05–0.25 M) and El-Shaboury et 
al. (2012) (citric acid concentration: 0.1–1 M) conducted 
some experiments at higher acid concentrations, whereas 
we aimed to use relatively low concentrations (0.006-0.02 
M) of acid to determine if acid concentration (B) affects 
the intensity of PL fluorescence.
Another parameter that may affect PL fluorescence 
intensity is temperature. It was previously shown that 
the fluorescence intensity of PL decreased at higher 
temperatures in both theoretical (due to a loss of energy 
by non-radiant emission processes) and experimental 
(Cagigal et al., 2001 and El-Shaboury et al., 2012; 
in experiments conducted at 20 °C ± 5 °C and room 
temperature, respectively) studies. Therefore, we 
conducted our experiments at temperatures ranging from 
20 °C to 30 °C.
The experimental  conditions for CCD and 
fluorescence intensity are presented in Table II. The 
objective of these experiments was to determine the 
conditions under which the highest PL fluorescence 
intensity could be obtained in the shortest possible run 
time.
The general function for a CCD with three factors 
(1):
IF = β0 + β1X1 + β2X2 + β3X3 + β12X1X2 + β13X1X3 
+ β23X2X3 + β11X21 + β11X12 + β22X22 + β33X32 + 
β123X1X2X3  (1)
where IF is the fluorescent intensity, β is the 
regression coefficient, and X1, X2, and X3 are factors A, 
B, and C, respectively. The data collected in Table II were 
analyzed with the Design-Expert 8.0 program following 
the methodology described above. The model was 
described by the following equation (2):
IF = +487.70 – 14.44A – 12.29B – 29.06C + 1388AB + 
15.13AC + 10.63BC – 42.0A2 – 47.85B2 – 27.52C2 (2)
According to the statistical parameters obtained 
from the ANOVA of the reduced model, the adjusted R2 
was 0.8007, which was within the acceptable limits of 
R2 ≥ 0.80 (Montgomery, 1991). The experimental results 
were fitted to a second-order model relating fluorescent 
intensity to the three factors. The P value for the reduced 
model was 0.045, and this model was significant (P< 0.05). 
TABLE II - Optimization of parameters for the central composite design and fluorescent intensity
Experiment A: pH B: Sulfurous acid 
concentration (M)
C: Temperature (°C) IF: Fluorescent intensity
1 3.00 0.020 30.00 309
2 2.25 0.013 17.00 520
3 1.50 0.006 30.00 308
4 3.00 0.006 30.00 319
5 1.00 0.013 25.00 450
6 2.25 0.013 33.40 400
7 3.50 0.013 25.00 388
8 3.00 0.020 20.00 338
9 1.50 0.006 20.00 440
10 2.25 0.025 25.00 385
11 1.50 0.020 30.00 306
12 2.25 0.001 25.00 420
13 3.00 0.006 20.00 327
14 1.50 0.020 20.00 332
15–20 2.25 0.013 25.00 482–486
Optimization of a spectrofluorimetric method based on a central composite design for the determination of potassium losartan 615
FIGURE 2 - Three-dimensional response surface plot for PL fluorescence intensity (IF). A) Variation of the response IF as a 
function of A and B, with temperature (C) as a fixed factor (21.6 °C), B) Variation of the response IF as a function of A and C, with 
sulfurous acid concentration (B) as a fixed factor (0.01 M), C) Variation of the response IF as a function of B and C, with pH (A) 
as a fixed factor (pH = 2).
The signal (response) to noise (deviation) ratio was 4.32, 
and a ratio >4 is desirable (Montgomery, 1991).
To understand the impact of each variable, three-
dimensional (3D) graphs were generated for the estimated 
responses, which were the bases of the polynomial model 
for the analysis of the interactive effect of the two factors 
on the fluorescence intensity within the experimental 
ranges shown in Figure 2. The interactions are discussed 
below.
Interactive effect of pH and acid concentration
It seems that fluorescence intensity increased 
with increasing pH until pH 2.00. In addition, the acid 
concentration slightly affected the fluorescence intensity, 
and the optimum acid concentration in our model was 
0.01 M. When the optimum pH and acid molarity were 
provided for the model, the fluorescence intensity reached 
its highest value. This interactive connection is shown in 
Figure 2A.
Interactive effect of temperature and pH
There was a strong interactive connection between 
temperature and pH. Fluorescence intensity increased 
as the temperature decreased. The effect of pH was also 
investigated, and pH 2.00 was found to be the optimum pH 
for the model. When these optimum pH and temperature 
conditions were provided, the fluorescence intensity 
reached its highest value, and this strong connection is 
shown in Figure 2B.
Interactive effect of temperature and acid 
concentration
An interactive connection was observed between 
temperature and acid molarity, and this connection is 
shown in Figure 2C as a 3D graph. This graph claims that 
fluorescence intensity increased as temperature decreased 
and at moderate acid molarity (0.01 M). According to the 
graph, the fluorescence intensity reached the highest value, 
at 0.01 M acid and 21.6 °C.
When all the data described above were integrated, 
the optimum values of pH (A), acid molarity (B), and 
temperature (C) for the proposed model were 2.00, 0.01 M, 
and 21.6 °C, respectively. When these conditions were 
applied, the theoretical fluorescence intensity was 501.3. 
The model was compared with the real samples, and the 
fluorescence intensity was determined to be 484.6 ± 1.63 
which is very close (96.7 ± 0.32%) to the theoretical value.
Validation Studies
Linearity/Working range
Linearity was analyzed by using PL calibration curves 
ranging from 0.025 to 0.5 μg/mL generated by diluting the 
PL stock solution (2 mg/mL) with 0.01 M sulfurous acid 
solution (pH 2). Linearity was evaluated by linear regression 
analysis, which was calculated by least-squares regression 
analysis. The fluorescence intensity was measured, and the 
mean linear regression equation was calculated based on 
six calibration curves as follows (3):
 IF: 893.77 C + 16.77   (3)
where C is the concentration (µg/mL) of PL, and IF is the 
fluorescence intensity of PL. The standard error of the 
intercept (1.397) and slope (0.560) and the correlation 
coefficients of the linear regression equations were also 
calculated. The high correlation coefficient (r = 0.9993) 
indicates that the method is linear.
Accuracy and precision
The accuracy and precision of the method were 
evaluated with QC samples of PL at concentrations 
of 0.05, 0.2, and 0.4 μg/mL on three consecutive days 
accompanied by a standard calibration curve on each 
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analytic run. The precision and accuracy of the assays 
were determined by the percent relative standard 
deviation (%RSD=100×standard deviation/mean) and 
relative error (RE= (calculated concentration-known 
concentration)×100/known concentration), respectively. 
The values of %RSD and RE for the intra-day and inter-
day variation are shown in Table III.
The % RSD values of the intra-day and inter-day 
precision for the proposed method were determined as 
the mean values of six determinations, and they ranged 
from 2.23 to 4.95 and 1.98 to 6.51, respectively. The RE 
values for the intra-day and inter-day accuracy studies of 
these methods were between 6.44 and 6.52 and 0.21 and 
7.06, respectively. These data supported the precision and 
accuracy of the method.
Sensitivity
The limit of detection (LOD) was determined by 
diluting the standard solution until the signal to noise (S/N) 
ratio was approximately 3. The limit of quantification 
(LOQ) was defined as the analyte concentration at the lowest 
measurable fluorescence intensity with acceptable precision 
(%RSD ≤ 10%). The LOD and LOQ for PL by using the 
proposed method were 0.002 µg/mL and 0.006 µg/mL, 
respectively.The calculated LOD was well below that 
required for PL analysis in pharmaceutical preparations.
Recovery
Recovery was determined by adding the PL QC 
samples (0.05, 0.2, and 0.4 μg/mL) to solutions (0.1 μg/mL) 
prepared from Cozaar® (50 mg), Eklips® (50 mg), 
Loxibin® (50 mg), Sarilen® (50 mg), and Sarvas® 
(50 mg) pharmaceutical preparations containing PL 
via the standard-addition technique, and then PL was 
quantified by the proposed method. The experiment was 
repeated six times at each QC concentration. The results 
are shown in Table IV, and the mean PL recovery values for 
Cozaar, Eklips, Loxibin, Sarilen, and Sarvas were 97.84%, 
99.78%, 99.30%, 97.01%, and 98.23%, respectively, with 
good accuracy.
TABLE III - Intra-day and inter-day precision and accuracy of the PL concentrations measured by using the proposed method
Addedb (µg/mL)
Intra-day Inter-day
Detected ± SD (µg/mL) RE %RSD Detected ± SD (µg/mL) RE %RSD
0.05 0.053 ± 0.002 6.52 4.95 0.050 ± 0.003 0.21 6.51
0.2 0.212 ± 0.004 6.49 2.23 0.214 ± 0.005 7.06 2.73
0.4 0.425 ± 0.010 6.44 2.57 0.422 ± 0.008 5.54 1.98
SD: standard deviation (n = 6), %RSD: relative standard deviation (n = 6), RE: relative error
TABLE IV - PL recovery from spiked pharmaceutical preparations
Drug Added (µg/mL) Detected ± SD (µg/mL) %Recovery %RSD
Cozaar 
0.1 µg/mL
0.05 0.051 ± 0.001 101.96 1.42
0.20 0.191 ± 0.002 95.47 0.82
0.40 0.384 ± 0.006 96.10 1.64
Eklips 
0.1 µg/mL 
0.05 0.052 ± 0.002 103.32 3.67
0.20 0.199 ± 0.001 99.94 0.68
0.40 0.384 ± 0.005 96.08 1.29
Loxibin 
0.1 µg/mL 
0.05 0.052 ± 0.002 104.55 3.28
0.20 0.193 ± 0.001 96.50 0.31
0.40 0.387 ± 0.006 96.86 1.63
Sarilen 
0.1 µg/mL 
0.05 0.049 ± 0.001 99.32 1.86
0.20 0.193 ± 0.004 96.25 2.29
0.40 0.382 ± 0.006 95.47 1.70
Sarvas 
0.1µg/mL 
0.05 0.051 ±0.003 101.74 5.62
0.20 0.194 ±0.002 96.99 1.24
0.40 0.384 ± 0.003 95.96 0.65
SD: standard deviation (n = 6), %RSD: relative standard deviation (n = 6)
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Stability
To determine the stability of PL, QC samples (0.025, 
0.2, and 0.4 μg/mL) were analyzed initially and at different 
time intervals (6 hours for room temperature [25 °C] and 
24, 48, and 60 hours for 4 °C and -20 °C). Stability was 
determined according to the acceptance criteria that the 
variation in recovery (%) should not be more than ±15 
according to the FDA guidelines (2013). According to 
the acceptance criteria, PL was stable for at least 6 hours 
at room temperature and for at least 60 hours at 4 °C and 
-20 °C.
Application and comparison of the proposed 
method to a reference method
The developed method was applied to the analysis 
of commercially available formulations (Cozaar®, Eklips®, 
Loxibin®, Sarilen®, and Sarvas® tablets). The fluorescence 
spectra of the pharmaceutical solutions are shown in 
Figure 3A–E.
To evaluate the amount of PL present in commercial 
pharmaceutical tablets, samples were analyzed twenty 
times after preparing the drug as described above in 
Sample Preparation of the Experimental section. The 
PL content of pharmaceutical tablets was calculated 
based on a standard calibration curve, and the obtained 
results, expressed as a percentage of the amount of drug 
listed on the label, are shown in Table V. These results 
were compared with previous results obtained with the 
reference HPLC method (Ansari et al., 2004) by a two 
one-sided equivalence test (TOST). The upper and lower 
acceptable limits for the difference in the amount of the 
active ingredient at each dosage have been predetermined 
as -3.0% to 3.0% (Lung et al., 2003). The critical t value 
for 28 degrees of freedom with a set for the TOST at 
0.05 was 1.701. The calculated confidence intervals 
for Cozaar® (-2.84 to -0.75), Eklips® (-2.65 to -0.28), 
Loxibin® (-2.82 to 0.87), Sarilen® (-2.46 to -0.21), and 
Sarvas® (-2.97 to -0.23) tablets were within the upper and 
lower limits (-3.0 to 3.0). Therefore, we concluded that 
the results obtained with the proposed spectrofluorimetric 
method and the HPLC reference assay were equivalent.
In addition, the performance of the proposed 
spectrofluorimetric method was compared to that 
of the HPLC and spectrophotometric methods. The 
HPLC method is sensitive and accurate; however, it 
requires time-consuming pretreatments (mobile phase 
preparation and column equilibration) before analysis. 
This technique is also expensive due to the cost of the 
column, mobile phase, and instrumentation. The previous 
spectrophotometric method is also rapid, but the accuracy 
and sensitivity are poorer than those of the HPLC method. 
The spectrofluorimetric method can be only applied to 
fluorescent compounds. Therefore, such methods are not 
as common as HPLC methods. However, the proposed 
spectrofluorimetric method is simpler than the HPLC 
method, it does not require instrument pretreatment, and 
it has excellent sensitivity for determining fluorescent 
compounds.
Based on our statistical data, we claim that our 
spectrofluorimetric method is more sensitive than the 
HPLC method because it has a lower LOQ (0.006 µg/mL). 
The LOQ for the published HPLC method ranged from 
0.15 to 4.20 µg/mL (Carlucci et al., 2000; Erk, 2001; 
FIGURE 3 - Fluorescence spectra of drug solutions (0.1 and 0.3 µg/mL) containing (A) Cozaar, (B) Eklips, (C) Loxibin, (D) 
Sarilen, and (E) Sarvas.
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Hertzog et al., 2002; Ansari et al., 2004; Bonfilio et al., 
2009), whereas the LOQ for published spectrophotometric 
methods ranged from 0.19 to 2.97 µg/mL (Prabhakar, 
Giridhar, 2002; Lastra et al., 2003; Sankar et al., 2003; 
Rahman, Siddiqui, Azmi, 2006; Latheeshjlal et al., 2010; 
El-Shiekh et al., 2011; Rao et al., 2011; Subbarao et al., 
2012), and the LOQ of a published spectrofluorimetric 
method for the analysis of PL in pharmaceuticals was 
0.5 µg/mL (Cagigal et al., 2001).
CONCLUSION
Here, a spectrofluorimetric method was developed 
to determine PL in pharmaceuticals. Three factors that 
play important roles in the fluorescence intensity of PL 
(pH, acid molarity, and temperature) were simultaneously 
optimized by using a response surface methodology 
based on the central composite design, which can save 
time and effort by estimating the optimum conditions. 
The validation study supported selection of the assay 
conditions by confirming that the assay was specific, 
sensitive, accurate, and precise. Additionally, this method 
does not involve many procedural steps, and it can be 
easily and directly applied to pharmaceuticals due to its 
rapidity and simplicity.
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